Fig. 2

Distribution of pT stages in surgical specimens according to HR and HER2 status. Distribution of pT in (a) all subtypes, (b) HR-positive HER2-negative, (c) HER2-positive, and (d) HR-negative HER2-negative lesions. HR, hormone receptor; HER2, human epidermal growth factor 2; DCIS, ductal carcinoma in situ